Phaseline

Companies › Aimei Vacin BioPharm (Zhejiang)

Aimei Vacin BioPharm (Zhejiang): clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
23-valent pneumococcal polysaccharide vaccine
Polysaccharide antigen vaccine against 23 pneumococcal serotypes
–Phase 3Pneumococcal DiseaseJul 2029
Tetanus Vaccine, Adsorbed (manufactured by AIM Persistence Biopharmaceutical Co.
Tetanus toxoid vaccine
–Phase 1TetanusDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07598890Tetanus Vaccine, Adsorbed (manufactured by AIM Persistence Biopharmaceutical Co.Phase 1TetanusInfectious diseaseDec 2026
NCT0604407723-valent pneumococcal polysaccharide vaccinePhase 3Pneumococcal DiseaseInfectious diseaseJul 2029

From the company's SEC filings

Complete response letters from FDA

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

InventVacc Biologicals MAXVAX Biotechnology Limited Liability Company Anhui Zhifei Longcom Biologic Pharmacy Biothervax Shenzhen Shenxin Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.